News Updates
Scope

Mon, May 18, 2026

1 updates
UPB
11:30 AM

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma – – Verekitug led to improvements in nasal polyp score (NPS) in participants with

Presentation / Abstract • Phase 2ATS poster presentation Mon, May 18, 2026upstreambio.com

Wed, May 13, 2026

1 updates
UPB
7:01 AM

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for mid-2026; Phase 3 initiations in both indications expected in Q1 2027 – – Phase 2 VENTURE trial in

Presentation / Abstract • Phase 2ATS abstract release Fri, May 15, 2026upstreambio.com

Fri, Apr 17, 2026

1 updates

Thu, Mar 26, 2026

1 updates

Sun, Mar 1, 2026

1 updates
UPB
9:45 AM

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of - 1.95 (p 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by

Presentation / Abstract • Phase 2upstreambio.com